Placental Aromatase Deficiency

Jump to navigation Jump to search

WikiDoc Resources for Placental Aromatase Deficiency

Articles

Most recent articles on Placental Aromatase Deficiency

Most cited articles on Placental Aromatase Deficiency

Review articles on Placental Aromatase Deficiency

Articles on Placental Aromatase Deficiency in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Placental Aromatase Deficiency

Images of Placental Aromatase Deficiency

Photos of Placental Aromatase Deficiency

Podcasts & MP3s on Placental Aromatase Deficiency

Videos on Placental Aromatase Deficiency

Evidence Based Medicine

Cochrane Collaboration on Placental Aromatase Deficiency

Bandolier on Placental Aromatase Deficiency

TRIP on Placental Aromatase Deficiency

Clinical Trials

Ongoing Trials on Placental Aromatase Deficiency at Clinical Trials.gov

Trial results on Placental Aromatase Deficiency

Clinical Trials on Placental Aromatase Deficiency at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Placental Aromatase Deficiency

NICE Guidance on Placental Aromatase Deficiency

NHS PRODIGY Guidance

FDA on Placental Aromatase Deficiency

CDC on Placental Aromatase Deficiency

Books

Books on Placental Aromatase Deficiency

News

Placental Aromatase Deficiency in the news

Be alerted to news on Placental Aromatase Deficiency

News trends on Placental Aromatase Deficiency

Commentary

Blogs on Placental Aromatase Deficiency

Definitions

Definitions of Placental Aromatase Deficiency

Patient Resources / Community

Patient resources on Placental Aromatase Deficiency

Discussion groups on Placental Aromatase Deficiency

Patient Handouts on Placental Aromatase Deficiency

Directions to Hospitals Treating Placental Aromatase Deficiency

Risk calculators and risk factors for Placental Aromatase Deficiency

Healthcare Provider Resources

Symptoms of Placental Aromatase Deficiency

Causes & Risk Factors for Placental Aromatase Deficiency

Diagnostic studies for Placental Aromatase Deficiency

Treatment of Placental Aromatase Deficiency

Continuing Medical Education (CME)

CME Programs on Placental Aromatase Deficiency

International

Placental Aromatase Deficiency en Espanol

Placental Aromatase Deficiency en Francais

Business

Placental Aromatase Deficiency in the Marketplace

Patents on Placental Aromatase Deficiency

Experimental / Informatics

List of terms related to Placental Aromatase Deficiency

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief:

Overview

Aromatase deficiency is an autosomal recessive disorder in which there is a decrease or absence in the level of aromatase in the body which leads to impairment in the conversion of androgens to estrogen. This is due to a genetic mutation in the CYP19A1, a subtype of [P450]. Patient affected by this disease typically presents with maternal virilization, amenorrhea in puberty in females. Males are rarely affected.

Historical Perspective

The evidence of the disease goes back to year 1991, when the first case of aromatase deficiency occurred [1]. Most of the cases were that of women during the third trimester of pregnancy presenting with maternal virilization resulting in hirsutism and acne.

Pathophysiology

CYP19A1 gene is responsible for the production of enzyme aromatase, which converts androgens to different forms of estrogen . Estrogen is involved in sexual development in females prior to birth and the levels peak during pregnancy. Mutation in CYP19A1 gene leads to deficiency or absence of activity of aromatase [2]. As a result, there is decrease in production of estrogen due to lack of conversion of androgens to estrogen and increase in testosterone and androstenedione levels. In pregnant women , excess androgens cross the placenta and enter into the maternal circulation leading to virilization. Female fetuses who are affected have ambiguous genitalia while males develop osteoporosis.

Causes

CYP19A1 gene mutation primarily causes Placental Aromatase Deficiency and the placenta is not capable of converting androgenic precursors of estrogen to estradiol. Mutations on exons 3,5 and 9 have been reported. Studies suggest that it is more prevalent in consanguinous marriages and both are heterozygous carriers of the mutation.

Differentiating Any Disease from other Diseases

Congenital adrenal hyperplasia can be considered as a differential in female patients. While, in male patients;

  • 5 alpha reductase deficiency :The levels of testosterone and estrogen are normal.
  • Estrogen resistance syndrome
  • 46,XY disorder of sex development due to isolated 17, 20 lyase deficiency
  • Congenital adrenal hyperplasia due to cytochrome P450 oxidoreductase deficiency
  • Congenital hypogonadotropic hypogonadism

can be considered as the differentials.

Epidemiology and Demographics

Placental Aromatase Deficiency is a rare autosomal recessive disorder. The prevalence is unknown . Approximately 20 cases have been described in the literature. [3]

Screening

There is insufficient evidence to recommend routine screening for [disease/malignancy].

OR

According to the [guideline name], screening for [disease name] is not recommended.

OR

According to the [guideline name], screening for [disease name] by [test 1] is recommended every [duration] among patients with [condition 1], [condition 2], and [condition 3].

Natural History , Complications and Prognosis

Placental aromatase deficiency is a rare entity.

As a result of defective synthesis of estrogen AD may result in :

  • Delayed Puberty
  • Insulin resistance
  • Polycystic ovarian disorder
  • Bone disorders

In patients with Aromatase deficiency lifetime hormone replacement therapy is mandatory. We can see osteoporosis as an outcome in male patients with late diagnosis, and these skeletal defects tend to remain even after hormonal treatment and sometimes require surgical correction. Moreover, the effects on glucose and lipid metabolism like adiposity and reproductive defects such as infertility are also not corrected by estradiol treatment.


Diagnosis

Diagnostic Study of Choice

The diagnosis of [disease name] is made when at least [number] of the following [number] diagnostic criteria are met: [criterion 1], [criterion 2], [criterion 3], and [criterion 4].

OR

The diagnosis of [disease name] is based on the [criteria name] criteria, which include [criterion 1], [criterion 2], and [criterion 3].

OR

The diagnosis of [disease name] is based on the [definition name] definition, which includes [criterion 1], [criterion 2], and [criterion 3].

OR

There are no established criteria for the diagnosis of [disease name].

History and Symptoms

The majority of patients with [disease name] are asymptomatic.

OR

The hallmark of [disease name] is [finding]. A positive history of [finding 1] and [finding 2] is suggestive of [disease name]. The most common symptoms of [disease name] include [symptom 1], [symptom 2], and [symptom 3]. Common symptoms of [disease] include [symptom 1], [symptom 2], and [symptom 3]. Less common symptoms of [disease name] include [symptom 1], [symptom 2], and [symptom 3].

Physical Examination

Patients with [disease name] usually appear [general appearance]. Physical examination of patients with [disease name] is usually remarkable for [finding 1], [finding 2], and [finding 3].

OR

Common physical examination findings of [disease name] include [finding 1], [finding 2], and [finding 3].

OR

The presence of [finding(s)] on physical examination is diagnostic of [disease name].

OR

The presence of [finding(s)] on physical examination is highly suggestive of [disease name].

Laboratory Findings

An elevated/reduced concentration of serum/blood/urinary/CSF/other [lab test] is diagnostic of [disease name].

OR

Laboratory findings consistent with the diagnosis of [disease name] include [abnormal test 1], [abnormal test 2], and [abnormal test 3].

OR

[Test] is usually normal among patients with [disease name].

OR

Some patients with [disease name] may have elevated/reduced concentration of [test], which is usually suggestive of [progression/complication].

OR

There are no diagnostic laboratory findings associated with [disease name].

Electrocardiogram

There are no ECG findings associated with [disease name].

OR

An ECG may be helpful in the diagnosis of [disease name]. Findings on an ECG suggestive of/diagnostic of [disease name] include [finding 1], [finding 2], and [finding 3].

X-ray

There are no x-ray findings associated with [disease name].

OR

An x-ray may be helpful in the diagnosis of [disease name]. Findings on an x-ray suggestive of/diagnostic of [disease name] include [finding 1], [finding 2], and [finding 3].

OR

There are no x-ray findings associated with [disease name]. However, an x-ray may be helpful in the diagnosis of complications of [disease name], which include [complication 1], [complication 2], and [complication 3].

Echocardiography or Ultrasound

There are no echocardiography/ultrasound findings associated with [disease name].

OR

Echocardiography/ultrasound may be helpful in the diagnosis of [disease name]. Findings on an echocardiography/ultrasound suggestive of/diagnostic of [disease name] include [finding 1], [finding 2], and [finding 3].

OR

There are no echocardiography/ultrasound findings associated with [disease name]. However, an echocardiography/ultrasound may be helpful in the diagnosis of complications of [disease name], which include [complication 1], [complication 2], and [complication 3].

CT scan

There are no CT scan findings associated with [disease name].

OR

[Location] CT scan may be helpful in the diagnosis of [disease name]. Findings on CT scan suggestive of/diagnostic of [disease name] include [finding 1], [finding 2], and [finding 3].

OR

There are no CT scan findings associated with [disease name]. However, a CT scan may be helpful in the diagnosis of complications of [disease name], which include [complication 1], [complication 2], and [complication 3].

MRI

There are no MRI findings associated with [disease name].

OR

[Location] MRI may be helpful in the diagnosis of [disease name]. Findings on MRI suggestive of/diagnostic of [disease name] include [finding 1], [finding 2], and [finding 3].

OR

There are no MRI findings associated with [disease name]. However, a MRI may be helpful in the diagnosis of complications of [disease name], which include [complication 1], [complication 2], and [complication 3].

Other Imaging Findings

There are no other imaging findings associated with [disease name].

OR

[Imaging modality] may be helpful in the diagnosis of [disease name]. Findings on an [imaging modality] suggestive of/diagnostic of [disease name] include [finding 1], [finding 2], and [finding 3].

Other Diagnostic Studies

There are no other diagnostic studies associated with [disease name].

OR

[Diagnostic study] may be helpful in the diagnosis of [disease name]. Findings suggestive of/diagnostic of [disease name] include [finding 1], [finding 2], and [finding 3].

OR

Other diagnostic studies for [disease name] include [diagnostic study 1], which demonstrates [finding 1], [finding 2], and [finding 3], and [diagnostic study 2], which demonstrates [finding 1], [finding 2], and [finding 3].


Treatment

Reference

  1. Shouzu M, Akasofu K, Harada T, Kubota Y (March 1991). "A new cause of female pseudohermaphroditism: placental aromatase deficiency". J. Clin. Endocrinol. Metab. 72 (3): 560–566. doi:10.1210/jcem-72-3-560. PMID 1825497.
  2. Aromatase Deficiency 18 August, 2020. Retrieved 13 June 2021
  3. Aromatase Deficiency 18 August, 2020. Retrieved 13 June 2021